Ask AI

Conference to Clinic: Integrating CD38-Based Quadruplet Therapy Into Care of Transplant-Ineligible and Transplant-Eligible NDMM

Enhance your understanding of anti-CD38 antibody-based quadruplet regimens for the management of newly diagnosed multiple myeloma. These therapies improve the care of transplant-ineligible, transplant-eligible, and underserved patients. Learn more through a certified on-demand webcast and accompanying downloadable slides.

Share

Program Content

Activities

CD38 Quadruplet Therapy in NDMM
Conference to Clinic: Integrating CD38-Based Quadruplet Therapy Into Care of Transplant-Ineligible and Transplant-Eligible NDMM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 21, 2025

Expires: January 20, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme